Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide (TCM-TMAO)
Primary Purpose
Acute Coronary Syndrome
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Compound Panax Notoginseng Granule
Placebo Granule
Sponsored by
About this trial
This is an interventional treatment trial for Acute Coronary Syndrome focused on measuring acute coronary syndrome, gut microbiota, Trimethylamine N-oxide, percutaneous coronary intervention
Eligibility Criteria
Inclusion Criteria:
- acute coronary syndrome (ACS), including ST segment elevate myocardial infarction(STEMI), Non-ST-segment elevation myocardial infarction(NSTEMI) and unstable angina(UA).
- TCM syndrome: Intermingled Phlegm and Blood Stasis.
- Aged 18 to 80 years old.
- sign a consent form.
Exclusion Criteria:
- Cardiogenic shock.
- Serious heart failure (NYHA IV or LVEF < 40%).
- With severe valvular heart disease.
- Severe hepatic or renal insufficiency, with serum Alanine aminotransferase ( ALT) 3 times higher than normal ceiling or serum creatinine not lower than 265 μmol/L.
- With acute cerebrovascular disease or severe mental illness.
- With active bleeding or severe hematopoietic system disease.
- With malignant tumor or life expectancy in less than three years.
- Pregnancy or ready to pregnant women, nursing mothers.
- History of taking antibiotics within the past two months.
- Participating in other clinical subjects .
- Failure to sign a consent form.
Sites / Locations
- Guangdong Provincial Hospital of Chinese MedicineRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Compound Panax Notoginseng Granule
Placebo Granule
Arm Description
On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
Outcomes
Primary Outcome Measures
the plasma level of TMAO
Trimethylamine-N-Oxide(μM) is relative to the prognostic of ACS.
the plasma level of TMAO
Trimethylamine-N-Oxide(μM) is relative to the prognostic of ACS.
Secondary Outcome Measures
metagenomic DNA sequencing analysis of faecal microbiome
high-throughput sequencing and big data analytics
metagenomic DNA sequencing analysis of faecal microbiome
high-throughput sequencing and big data analytics
major adverse cardiac event
frequency of the reported cardiovascular events (defined as death, non fatal myocardial infarction,target vessel revascularization and stent thrombosis )
cardiac function
left ventricular ejection fraction(LVEF) evaluated by echo
cardiac function
left ventricular ejection fraction(LVEF) evaluated by echo
Seattle Angina Questionnaire score
The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception).
The traditional Chinese medicine syndrome scale
The score of phlegm and of blood stasis syndromes is evaluated by Phlegm and blood stasis syndrome questionnaire.
lipid metabolism
low-density lipoprote in cholesterol in mmol/L
lipid metabolism
total cholesterol in cholesterol in mmol/L
inflammatory factors
C-reactive protein in mg/L
platelet function
maximal aggregation rate of platelet in percent
cardiac biomarkers of necrosis
cardiac troponin T (cTnT) in ug/L
Full Information
NCT ID
NCT03186625
First Posted
June 7, 2017
Last Updated
December 5, 2017
Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Collaborators
Beijing Genomics Institute
1. Study Identification
Unique Protocol Identification Number
NCT03186625
Brief Title
Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide
Acronym
TCM-TMAO
Official Title
Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide in Acute Coronary Syndromes : A Randomized Placebo Controlled Trial
Study Type
Interventional
2. Study Status
Record Verification Date
December 2017
Overall Recruitment Status
Unknown status
Study Start Date
December 5, 2017 (Actual)
Primary Completion Date
May 31, 2018 (Anticipated)
Study Completion Date
August 31, 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Guangdong Provincial Hospital of Traditional Chinese Medicine
Collaborators
Beijing Genomics Institute
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
5. Study Description
Brief Summary
Recent studies highlight the participation of gut microbes in the pathogenesis of both atherosclerotic heart disease and its adverse thrombotic events. Trimethylamine N-oxide (TMAO) is a plasma metabolite shown to be formed through a metaorganismal pathway involving nutrient precursors abundant in a Western diet and the sequential action of gut microbiota. Numerous studies reveal an association between systemic TMAO levels and cardiovascular risks in a variety of stable cohorts. The purpose of this study is to evaluate the efficacy of traditional Chinese Medicine formular (Compound pseudo-ginseng granules ) on the level of TMAO for the patient with acute coronary syndrome(ACS) undergoing percutaneous coronary intervention. 80 patients with ACS would be randomly allocated into interventional group(IG) and control group(CG). The patients in the IG would be administered by oral Compound pseudo-ginseng granules (twice per day ) for 90 days and those in the CG would receive the placebo twice per day during the same period. All of subjects would be administered with standard therapy in accordance with AHA/ACC guideline for ST-elevation myocardial infarction(STEMI) and Non ST-elevation myocardial infarction(NSTEMI).The primary endpoint is the plasma level of TMAO at 90-day follow-up. The second endpoint is the level of lipid, score of The Seattle Angina, fecal DNA extraction and pyrosequencing.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Coronary Syndrome
Keywords
acute coronary syndrome, gut microbiota, Trimethylamine N-oxide, percutaneous coronary intervention
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
80 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Compound Panax Notoginseng Granule
Arm Type
Experimental
Arm Description
On the basis of the standard treatment for ACS,eligible participants are randomized to receive Compound Panax Notoginseng Granule when they enroll.
Arm Title
Placebo Granule
Arm Type
Placebo Comparator
Arm Description
On the basis of the standard treatment for ACS,eligible participants are randomized to receive Placebo Granule when they enroll.
Intervention Type
Drug
Intervention Name(s)
Compound Panax Notoginseng Granule
Intervention Description
Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.
Frequency:two times a day, one package per time. Duration:three months.
Intervention Type
Drug
Intervention Name(s)
Placebo Granule
Intervention Description
Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
Primary Outcome Measure Information:
Title
the plasma level of TMAO
Description
Trimethylamine-N-Oxide(μM) is relative to the prognostic of ACS.
Time Frame
baseline
Title
the plasma level of TMAO
Description
Trimethylamine-N-Oxide(μM) is relative to the prognostic of ACS.
Time Frame
90-days post-procedure
Secondary Outcome Measure Information:
Title
metagenomic DNA sequencing analysis of faecal microbiome
Description
high-throughput sequencing and big data analytics
Time Frame
baseline
Title
metagenomic DNA sequencing analysis of faecal microbiome
Description
high-throughput sequencing and big data analytics
Time Frame
90-days post-procedure
Title
major adverse cardiac event
Description
frequency of the reported cardiovascular events (defined as death, non fatal myocardial infarction,target vessel revascularization and stent thrombosis )
Time Frame
90-days post-procedure
Title
cardiac function
Description
left ventricular ejection fraction(LVEF) evaluated by echo
Time Frame
baseline
Title
cardiac function
Description
left ventricular ejection fraction(LVEF) evaluated by echo
Time Frame
90-day at follow-up
Title
Seattle Angina Questionnaire score
Description
The Seattle Angina Questionnaire is a valid and reliable instrument that measures five clinically important dimensions of health in patients with coronary artery disease (physical limitation, anginal stability, anginal frequency, treatment satisfaction, and disease perception).
Time Frame
90-days
Title
The traditional Chinese medicine syndrome scale
Description
The score of phlegm and of blood stasis syndromes is evaluated by Phlegm and blood stasis syndrome questionnaire.
Time Frame
change from baseline at 90-days
Title
lipid metabolism
Description
low-density lipoprote in cholesterol in mmol/L
Time Frame
change from baseline at 90-days
Title
lipid metabolism
Description
total cholesterol in cholesterol in mmol/L
Time Frame
change from baseline at 90-days
Title
inflammatory factors
Description
C-reactive protein in mg/L
Time Frame
change from baseline at 90-days
Title
platelet function
Description
maximal aggregation rate of platelet in percent
Time Frame
change from Baseline at 90-days
Title
cardiac biomarkers of necrosis
Description
cardiac troponin T (cTnT) in ug/L
Time Frame
Change from Baseline at 5 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
80 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
acute coronary syndrome (ACS), including ST segment elevate myocardial infarction(STEMI), Non-ST-segment elevation myocardial infarction(NSTEMI) and unstable angina(UA).
TCM syndrome: Intermingled Phlegm and Blood Stasis.
Aged 18 to 80 years old.
sign a consent form.
Exclusion Criteria:
Cardiogenic shock.
Serious heart failure (NYHA IV or LVEF < 40%).
With severe valvular heart disease.
Severe hepatic or renal insufficiency, with serum Alanine aminotransferase ( ALT) 3 times higher than normal ceiling or serum creatinine not lower than 265 μmol/L.
With acute cerebrovascular disease or severe mental illness.
With active bleeding or severe hematopoietic system disease.
With malignant tumor or life expectancy in less than three years.
Pregnancy or ready to pregnant women, nursing mothers.
History of taking antibiotics within the past two months.
Participating in other clinical subjects .
Failure to sign a consent form.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Lei Wang, Ph.D & M.D
Phone
86-20-81887233-32801
Email
Dr.wanglei@139.com
First Name & Middle Initial & Last Name or Official Title & Degree
Shuai Mao, M.D
Phone
+8613724078381
Email
maoshuaitcm@163.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaoyan Li, Master
Organizational Affiliation
Guangdong Provincial Hospital of Traditional Chinese Medicine
Official's Role
Study Director
Facility Information:
Facility Name
Guangdong Provincial Hospital of Chinese Medicine
City
Guangzhou
State/Province
Guangdong
ZIP/Postal Code
510120
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Lei Wang, M.D
Phone
8620-81887233-32801
Email
Dr.wanglei@139.com
12. IPD Sharing Statement
Learn more about this trial
Impact of Traditional Chinese Medicine on the Gut Microbiota-dependent Trimethylamine N-oxide
We'll reach out to this number within 24 hrs